SCHEMBL4293425

SCHEMBL4293425

Cc1ccc2c(C3C(c4c[nH]c5ccccc45)=C(O)C(=O)N3CCCn3ccnc3)c[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
TP53 P04637 6/20 0.47
MDM2 Q00987 5/20 0.47
GSK3B P49841 1/20 0.44
QPCT Q16769 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
ANXA2 P07355 1/20 0.41
S100A10 P60903 1/20 0.41
JAK1 P23458 2/20 0.40
JAK3 P52333 2/20 0.40
PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4300546 0.93 QPCT (0.49) KDM4ETP53MDM2GSK3BQPCT
SCHEMBL4297741 0.90 KDM4E (0.51) KDM4ETP53MDM2ALDH1A1MEN1
SCHEMBL3810523 0.88 KDM4E (0.62) KDM4ETP53MDM2GSK3BQPCT
SCHEMBL4293364 0.87 KDM4E (0.51) KDM4ETP53MDM2GSK3BQPCT
SCHEMBL4295237 0.87 KDM4E (0.55) KDM4ETP53MDM2ALDH1A1MEN1
SCHEMBL4301880 0.86 QPCT (0.48) KDM4ETP53MDM2GSK3BQPCT
SCHEMBL4303876 0.85 RXFP1 (0.48) KDM4ETP53MDM2GSK3BQPCT
SCHEMBL4298706 0.85 KDM4E (0.52) KDM4ETP53MDM2GSK3BQPCT
SCHEMBL4298476 0.84 KDM4E (0.53) KDM4ETP53MDM2ALDH1A1MEN1
SCHEMBL3815347 0.84 QPCT (0.47) KDM4ETP53MDM2GSK3BQPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US claimed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US claimed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL KDM4E 2532/4885TP53 4054/4885MDM2 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.